Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine.
Vaccine
; 31(37): 4024-32, 2013 Aug 20.
Article
en En
| MEDLINE
| ID: mdl-23707166
Palabras clave
ASR; Anti-HBs; Chronic kidney disease; Cost-effectiveness analysis; Diabetes; End-stage renal disease; FHF'; HBV; HBsAg; HCC; Hepatitis B; ICER; International travelers; QALY; SPR; Vaccine; age-standardized rate; antibody to hepatitis B surface antigen; fulminant hepatic failure; hepatitis B surface antigen; hepatitis B virus; hepatocellular carcinoma; incremental cost-effectiveness ratio; quality adjusted life-year; seroprotection rate (anti-HBs ≥10 mIU/mL)
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Vacunas contra Hepatitis B
/
Hepatitis B
Tipo de estudio:
Health_economic_evaluation
/
Prognostic_studies
/
Risk_factors_studies
Aspecto:
Patient_preference
Límite:
Adolescent
/
Adult
/
Aged
/
Humans
/
Middle aged
Idioma:
En
Revista:
Vaccine
Año:
2013
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Países Bajos